melanoma | Research | Treatment | 10 pages | source: Annals of Surgical Oncology | Added Nov 27, 2021
Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.
This study evaluated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) after failure of immunotherapy for the treatment of patients with unresectable metastatic melanoma. The data showed that T-VEC after the failure of immunotherapy is safe and effective in these patients.
non-hodgkin lymphoma | Research | Treatment | 10 pages | source: Lancet (London, England) | Added Nov 21, 2021
How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?
The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL).
The study showed that this medication has promising effectiveness and safety in these patients.
diabetes mellitus | Research | Treatment | 10 pages | source: Diabetes, Obesity and Metabolism | Added Nov 21, 2021
How effective is iGlarLixi in patients with uncontrolled type 2 diabetes?
This study evaluated the effectiveness of insulin glargine 100U/ml (iGlar; Lantus) and lixisenatide (Lixi; Lyxumia) combined (iGlarLixi; Soliqua) compared with each of the two drugs alone in patients with type 2 diabetes (T2D) that was uncontrolled with 2 anti-diabetic oral drugs. The data showed that iGlarLixi resulted in better glucose control compared to iGlar or Lixi, and did not cause abnormally low blood glucose (hypoglycemia).
multiple myeloma | Research | Treatment | 10 pages | source: The Lancet. Oncology | Added Nov 21, 2021
Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.
This study investigated the use of daratumumab (Darzalex) as maintenance therapy following autologous stem-cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). The data showed that maintenance therapy with daratumumab resulted in significant improvements in outcomes compared to observation only in patients that received ASCT.
prostate cancer | Research | 10 pages | source: Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer | Added Nov 14, 2021
Reviewing the changes in quality of life and lower urinary tract symptoms in patients with prostate cancer following prostate surgery
This review explained the changes in lower urinary tract symptoms (LUTS) and quality of life (QoL) that occurred over time in patients with prostate cancer following radical prostatectomy (RP; removal of the prostate). The data showed that 6 to 12 months are required for LUTS improvement after RT.
non-hodgkin lymphoma | Research | Treatment | 10 pages | source: Blood advances | Added Nov 14, 2021
Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma
The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL).
This study concluded that this treatment can be effective in these patients.
leukemia | Research | 10 pages | source: Cancer Medicine | Added Nov 14, 2021
Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs
This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new targeted therapy drugs.
This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.
melanoma | Research | Treatment | 10 pages | source: Nature Medicine | Added Nov 14, 2021
Evaluating the effectiveness and safety of T-VEC plus surgery for the treatment of patients with resectable advanced stage melanoma.
This study compared the effectiveness and safety of talimogene laherparepvec (Imlygic; T-VEC) plus surgery versus surgery alone for the treatment of patients with resectable advanced stage (III or IV) melanoma. The data showed that T-VEC plus surgery was safe and effective for these patients.
leukemia | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Nov 14, 2021
Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.
This study investigated the effectiveness and safety of fixed-duration treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with previously untreated chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that fixed-duration treatment with ibrutinib plus venetoclax was safe and effective for these patients.
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Nov 14, 2021
Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.
This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical, functional, and oncological outcomes compared to LRP in these patients.
